Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 19/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430483 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2PBRM1L3MBTL1BRD4 | |
| SCHEMBL428348 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2PBRM1L3MBTL1BRD4 | |
| SCHEMBL430718 | 0.74 | L3MBTL1 (0.48) | SMN1; SMN2PBRM1L3MBTL1BRD4 | |
| SCHEMBL6205188 | 0.63 | LMNA (0.43) | — | |
| SCHEMBL11777629 | 0.62 | SMN1; SMN2 (1.00) | SMN1; SMN2PBRM1L3MBTL1BRD4 | |
| SCHEMBL11779422 | 0.60 | KDM4E (0.61) | SMN1; SMN2PBRM1L3MBTL1BRD4 | |
| SCHEMBL6202922 | 0.60 | PNMT (0.47) | SMN1; SMN2 | |
| SCHEMBL25308970 | 0.59 | L3MBTL1 (0.61) | L3MBTL1BRD4 | |
| SCHEMBL18323654 | 0.59 | SMN1; SMN2 (0.44) | SMN1; SMN2PBRM1L3MBTL1BRD4 | |
| SCHEMBL6206376 | 0.59 | IDO1 (0.48) | SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | SMN1; SMN2 3271/4885PBRM1 1014/4885L3MBTL1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.